Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore
Abstract
:1. Introduction
2. Diagnosis
3. Treatment
3.1. Surgery
3.2. Radiation Therapy
3.3. Chemotherapy
3.4. Hormonal Therapy
3.5. Targeted Therapy
3.6. Immunotherapy
4. Obstetrical Care
5. Long-Term Neonatal Outcomes
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Salani, R.; Billingsley, C.C.; Crafton, S.M. Cancer and pregnancy: An overview for obstetricians and gynecologists. Am. J. Obstet. Gynecol. 2014, 211, 7–14. [Google Scholar] [CrossRef] [PubMed]
- Esposito, S.; Tenconi, R.; Preti, V.; Groppali, E.; Principi, N. Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes. Medicine 2016, 95, e4899. [Google Scholar] [CrossRef] [PubMed]
- Parazzini, F.; Franchi, M.; Tavani, A.; Negri, E.; Peccatori, F.A. Frequency of pregnancy related cancer: A population based linkage study in Lombardy, Italy. Int. J. Gynecol. Cancer 2017, 27, 613–619. [Google Scholar] [CrossRef] [PubMed]
- Amant, F.; Loibl, S.; Neven, P.; Van Calsteren, K. Breast cancer in pregnancy. Lancet 2012, 379, 570–579. [Google Scholar] [CrossRef]
- Ulery, M.; Carter, L.; McFarlin, B.L.; Giurgescu, C. Pregnancy-associated breast cancer: Significance of early detection. J. Midwifery Women’s Health 2009, 54, 357–363. [Google Scholar] [CrossRef] [PubMed]
- Li, C.I.; Daling, J.R.; Malone, K.E. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J. Clin. Oncol. 2003, 21, 28–34. [Google Scholar] [CrossRef] [PubMed]
- Aziz, S.; Pervez, S.; Khan, S.; Siddiqui, T.; Kayani, N.; Israr, M.; Rahbar, M. Case control study of novel prognostic markers and disease outcome in pregnancy/lactation-associated breast carcinoma. Pathol. Res. Pract. 2003, 199, 15–21. [Google Scholar] [CrossRef]
- Bonilla, L.; Ben-Aharon, I.; Vidal, L.; Gafter-Gvili, A.; Leibovici, L.; Stemmer, S.M. Dose-dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. J. Natl. Cancer Inst. 2010, 102, 1845–1854. [Google Scholar] [CrossRef]
- Amant, F.; von Minckwitz, G.; Han, S.N.; Bontenbal, M.; Ring, A.E.; Giermek, J.; Wildiers, H.; Fehm, T.; Linn, S.C.; Schlehe, B.; et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: Results from an international collaborative study. J. Clin. Oncol. 2013, 31, 2532–2539. [Google Scholar] [CrossRef]
- Lu, D.; Ludvigsson, J.F.; Smedby, K.E.; Fall, K.; Valdimarsdóttir, U.; Cnattingius, S.; Fang, F. Maternal cancer during pregnancy and risks of stillbirth and infant mortality. J. Clin. Oncol. 2017, 35, 1522–1529. [Google Scholar] [CrossRef]
- Niu, X.; Li, C.I.; Mueller, B.A. Obstetrical and infant outcomes among women with neoplasms during pregnancy. Cancer Causes Control 2019, 30, 651–661. [Google Scholar] [CrossRef] [PubMed]
- Shechter Maor, G.; Czuzoj-Shulman, N.; Spence, A.R.; Abenhaim, H.A. Neonatal outcomes of pregnancy-associated breast cancer: Population-based study on 11 million births. Breast J. 2019, 25, 86–90. [Google Scholar] [CrossRef] [PubMed]
- Loibl, S.; Han, S.N.; von Minckwitz, G.; Bontenbal, M.; Ring, A.; Giermek, J.; Fehm, T.; Van Calsteren, K.; Linn, S.C.; Schlehe, B.; et al. Treatment of breast cancer during pregnancy: An observational study. Lancet Oncol. 2012, 13, 887–896. [Google Scholar] [CrossRef]
- de Haan, J.; Verheecke, M.; Van Calsteren, K.; Van Calster, B.; Shmakov, R.G.; Gziri, M.M.; Halaska, M.J.; Fruscio, R.; Lok, C.A.; Boere, I.A.; et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: A 20-year international cohort study of 1170 patients. Lancet Oncol. 2018, 19, 337–346. [Google Scholar] [CrossRef]
- Johannsson, O.; Loman, N.; Borg, A.; Olsson, H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 1998, 352, 1359–1360. [Google Scholar] [CrossRef]
- Jafari, M.; Gity, M.; Olfatbakhsh, A.; Rezaei-Kalantari, K.; Hashemi, E.A. Pregnancy-associated Breast Cancer: A Review of Imaging Modalities. Int. J. Cancer Manag. 2018, 11, e65444. [Google Scholar] [CrossRef]
- Bae, S.Y.; Jung, S.P.; Jung, E.S.; Park, S.M.; Lee, S.K.; Yu, J.H.; Lee, J.E.; Kim, S.W.; Nam, S.J. Clinical characteristics and prognosis of pregnancy-associated breast cancer: Poor survival of luminal b subtype. Oncology 2018, 95, 163–169. [Google Scholar] [CrossRef]
- Shoemaker, M.L.; White, M.C.; Wu, M.; Weir, H.K.; Romieu, I. Differences in breast cancer incidence among young women aged 20–49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–2013. Breast Cancer Res. Treat. 2018, 169, 595–606. [Google Scholar] [CrossRef]
- Wang, B.; Yang, Y.; Jiang, Z.; Zhao, J.; Mao, Y.; Liu, J.; Zhang, J. Clinicopathological characteristics, diagnosis, and prognosis of pregnancy-associated breast cancer. Thorac. Cancer 2019, 10, 1060–1068. [Google Scholar] [CrossRef]
- Vashi, R.; Hooley, R.; Butler, R.; Geisel, J.; Philpotts, L. Breast imaging of the pregnant and lactating patient: Imaging modalities and pregnancy-associated breast cancer. Am. J. Roentgenol. 2013, 200, 321–328. [Google Scholar] [CrossRef]
- Sechopoulos, I.; Suryanarayanan, S.; Vedantham, S.; D’Orsi, C.J.; Karellas, A. Radiation dose to organs and tissues from mammography: Monte Carlo and phantom study. Radiology 2008, 246, 434–443. [Google Scholar] [CrossRef] [PubMed]
- Kanal, E.; Barkovich, A.J.; Bell, C.; Borgstede, J.P.; Bradley, W.G., Jr.; Froelich, J.W.; Gilk, T.; Gimbel, J.R.; Gosbee, J.; Kuhni-Kaminski, E.; et al. ACR guidance document for safe MR practices: 2007. Am. J. Roentgenol. 2007, 188, 1447–1474. [Google Scholar] [CrossRef] [PubMed]
- Amant, F.; Deckers, S.; Van Calsteren, K.; Loibl, S.; Halaska, M.; Brepoels, L.; Beijnen, J.; Cardoso, F.; Gentilini, O.; Lagae, L.; et al. Breast cancer in pregnancy: Recommendations of an international consensus meeting. Eur. J. Cancer 2010, 46, 3158–3168. [Google Scholar] [CrossRef] [PubMed]
- Soricelli, A. International Atomic Energy Agency: Nuclear Medicine Resources Manual; 55 illustrations; IAEA: Vienna, Austria, 2007; 532p, ISBN 92-0-107504-9. [Google Scholar]
- Azim, H.A., Jr. Managing Cancer During Pregnancy; Springer: Cham, Switzerland, 2016. [Google Scholar]
- Cohen-Kerem, R.; Railton, C.; Oren, D.; Lishner, M.; Koren, G. Pregnancy outcome following non-obstetric surgical intervention. Am. J. Surg. 2005, 190, 467–473. [Google Scholar] [CrossRef]
- Mhuireachtaigh, R.N.; O’Gorman, D.A. Anesthesia in pregnant patients for nonobstetric surgery. J. Clin. Anesth. 2006, 18, 60–66. [Google Scholar] [CrossRef]
- Toesca, A.; Gentilini, O.; Peccatori, F.; Azim, H.A.; Amant, F. Locoregional treatment of breast cancer during pregnancy. Gynecol. Surg. 2014, 11, 279–284. [Google Scholar] [CrossRef]
- Lohsiriwat, V.; Peccatori, F.A.; Martella, S.; Azim, H.A., Jr.; Sarno, M.A.; Galimberti, V.; De Lorenzi, F.; Intra, M.; Sangalli, C.; Rotmensz, N.; et al. Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast 2013, 22, 657–660. [Google Scholar] [CrossRef]
- Lyman, G.H.; Somerfield, M.R.; Bosserman, L.D.; Perkins, C.L.; Weaver, D.L.; Giuliano, A.E. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 2016, 35, 561–564. [Google Scholar] [CrossRef]
- Keleher, A.; Wendt, R., III; Delpassand, E.; Stachowiak, A.M.; Kuerer, H.M. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004, 10, 492–495. [Google Scholar] [CrossRef]
- Gentilini, O.; Cremonesi, M.; Trifiro, G.; Ferrari, M.; Baio, S.; Caracciolo, M.; Rossi, A.; Smeets, A.; Galimberti, V.; Luini, A.; et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann. Oncol. 2004, 15, 1348–1351. [Google Scholar] [CrossRef]
- Gentilini, O.; Cremonesi, M.; Toesca, A.; Colombo, N.; Peccatori, F.; Sironi, R.; Sangalli, C.; Rotmensz, N.; Pedroli, G.; Viale, G.; et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 78–83. [Google Scholar] [CrossRef] [PubMed]
- Pandit-Taskar, N.; Dauer, L.T.; Montgomery, L.; Germain, J.S.; Zanzonico, P.B.; Divgi, C.R. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J. Nucl. Med. 2006, 47, 1202–1208. [Google Scholar] [PubMed]
- Gropper, A.B.; Calvillo, K.Z.; Dominici, L.; Troyan, S.; Rhei, E.; Economy, K.E.; Tung, N.M.; Schapira, L.; Meisel, J.L.; Partridge, A.H.; et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann. Surg. Oncol. 2014, 21, 2506–2511. [Google Scholar] [CrossRef] [PubMed]
- Tsoutsou, P.G.; Koukourakis, M.I.; Azria, D.; Belkacémi, Y. Optimal timing for adjuvant radiation therapy in breast cancer: A comprehensive review and perspectives. Crit. Rev. Oncol. 2009, 71, 102–116. [Google Scholar] [CrossRef]
- Kal, H.B.; Struikmans, H. Radiotherapy during pregnancy: Fact and fiction. Lancet Oncol. 2005, 6, 328–333. [Google Scholar] [CrossRef]
- Streffer, C.; Shore, R.; Konermann, G.; Meadows, A.; Uma, P.D.; Preston, J.W.; Holm, L.; Stather, J.; Mabuchi, K. Biological effects after prenatal irradiation (embryo and fetus). A report of the International Commission on Radiological Protection. Ann. ICRP 2003, 33, 5–206. [Google Scholar]
- Pregnancy and medical radiation. Ann ICRP 2000, 30, 1–43.
- Schull, W.J.; Otake, M. Effect on Intelligence of Prenatal Exposure to Ionizing Radiation; Technical report; Radiation Effects Research Foundation: Hiroshima, Japan, 1987. [Google Scholar]
- Schull, W.J.; Otake, M.; Yoshimaru, H. Effect on Intelligence Test Score of Prenatal Exposure to Ionizing Radiation in Hiroshima and Nagasaki; Technical report; Radiation Effects Research Foundation: Hiroshima, Japan, 1988. [Google Scholar]
- Otake, M. Threshold for radiation-related severe mental retardation in prenatally exposed A-bomb survivors: A re-analysis. Int. J. Radiat. Biol. 1996, 70, 755–763. [Google Scholar] [CrossRef]
- Otake, M. Radiation-related brain damage and growth retardation among the prenatally exposed atomic bomb survivors. Int. J. Radiat. Biol. 1998, 74, 159–171. [Google Scholar] [CrossRef]
- Fenig, E.; Mishaeli, M.; Kalish, Y.; Lishner, M. Pregnancy and radiation. Cancer Treat. Rev. 2001, 27, 1–7. [Google Scholar] [CrossRef]
- Van der Giessen, P.H. Measurement of the peripheral dose for the tangential breast treatment technique with Co-60 gamma radiation and high energy X-rays. Radiother. Oncol. 1997, 42, 257–264. [Google Scholar] [CrossRef]
- Antypas, C.; Sandilos, P.; Kouvaris, J.; Balafouta, E.; Karinou, E.; Kollaros, N.; Vlahos, L. Fetal dose evaluation during breast cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1998, 40, 995–999. [Google Scholar] [CrossRef]
- Mazonakis, M.; Varveris, H.; Damilakis, J.; Theoharopoulos, N.; Gourtsoyiannis, N. Radiation dose to conceptus resulting from tangential breast irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55, 386–391. [Google Scholar] [CrossRef]
- Han, B.; Bednarz, B.; Xu, X.G. A study of the shielding used to reduce leakage and scattered radiation to the fetus in a pregnant patient treated with a 6-MV external X-ray beam. Health Phys. 2009, 97, 581. [Google Scholar] [CrossRef]
- Ngu, S.C.; Duval, P.; Collins, C. Foetal radiation dose in radiotherapy for breast cancer. Australas. Radiol. 1992, 36, 321–322. [Google Scholar] [CrossRef]
- Leslie, K.K.; Koil, C.; Rayburn, W.F. Chemotherapeutic drugs in pregnancy. Obstet. Gynecol. Clin. 2005, 32, 627–640. [Google Scholar] [CrossRef]
- Abadi, U.; Koren, G.; Lishner, M. Leukemia and lymphoma in pregnancy. Hematol. Clin. 2011, 25, 277–291. [Google Scholar] [CrossRef]
- Cardonick, E.; Iacobucci, A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004, 5, 283–291. [Google Scholar] [CrossRef]
- Doll, D.C.; Ringenberg, Q.S.; Yarbro, J.W. Management of cancer during pregnancy. Arch. Intern. Med. 1988, 148, 2058–2064. [Google Scholar] [CrossRef]
- Ring, A.E.; Smith, I.E.; Jones, A.; Shannon, C.; Galani, E.; Ellis, P.A. Chemotherapy for breast cancer during pregnancy: An 18-year experience from five London teaching hospitals. J. Clin. Oncol. 2005, 23, 4192–4197. [Google Scholar] [CrossRef]
- Hahn, K.M.; Johnson, P.H.; Gordon, N.; Kuerer, H.; Middleton, L.; Ramirez, M.; Yang, W.; Perkins, G.; Hortobagyi, G.N.; Theriault, R.L. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006, 107, 1219–1226. [Google Scholar] [CrossRef] [PubMed]
- Program, N.T. NTP monograph: Developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. NTP Monogr. 2013, 2, i-214. [Google Scholar]
- Berveiller, P.; Mir, O.; Degrelle, S.A.; Tsatsaris, V.; Selleret, L.; Guibourdenche, J.; Evain-Brion, D.; Fournier, T.; Gil, S. Chemotherapy in pregnancy: Exploratory study of the effects of paclitaxel on the expression of placental drug transporters. Investig. New Drugs 2019, 37, 1075–1085. [Google Scholar] [CrossRef] [PubMed]
- O’Laughlin, A.; Thus, S.; Fleischer, L.; Akoto, S.; Cardonick, E. Safety of Taxane Chemotherapy in Breast Cancer During Pregnancy [28O]. Obstet. Gynecol. 2019, 133, 169–170. [Google Scholar] [CrossRef]
- Van Calsteren, K.; Verbesselt, R.; Beijnen, J.; Devlieger, R.; De Catte, L.; Chai, D.; Van Bree, R.; Heyns, L.; de Hoon, J.; Amant, F. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol. Oncol. 2010, 119, 594–600. [Google Scholar] [CrossRef]
- Van Calsteren, K.; Verbesselt, R.; Devlieger, R.; De Catte, L.; Chai, D.C.; Van Bree, R.; Heyns, L.; Beijnen, J.; Demarsin, S.; de Bruijn, E.; et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int. J. Gynecol. Cancer 2010, 20, 1456–1464. [Google Scholar]
- Van Calsteren, K.; Verbesselt, R.; Ottevanger, N.; Halaska, M.; Heyns, L.; Van Bree, R.; de Bruijn, E.; Chai, D.; Delforge, M.; Noens, L.; et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: A preclinical and clinical study. Acta Obstet. Gynecol. Scand. 2010, 89, 1338–1345. [Google Scholar] [CrossRef]
- Van Hasselt, J.; Van Calsteren, K.; Heyns, L.; Han, S.; Mhallem Gziri, M.; Schellens, J.; Beijnen, J.; Huitema, A.; Amant, F. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann. Oncol. 2014, 25, 2059–2065. [Google Scholar] [CrossRef]
- Loibl, S.; Von Minckwitz, G.; Gwyn, K.; Ellis, P.; Blohmer, J.U.; Schlegelberger, B.; Keller, M.; Harder, S.; Theriault, R.L.; Crivellari, D.; et al. Breast carcinoma during pregnancy: International recommendations from an expert meeting. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2006, 106, 237–246. [Google Scholar] [CrossRef]
- Cardonick, E.; Gilmandyar, D.; Somer, R.A. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet. Gynecol. 2012, 120, 1267–1272. [Google Scholar] [CrossRef]
- Schuurman, T.; Witteveen, P.; van der Wall, E.; Passier, J.; Huitema, A.; Amant, F.; Lok, C. Tamoxifen and pregnancy: An absolute contraindication? Breast Cancer Res. Treat. 2019, 175, 17–25. [Google Scholar] [CrossRef] [PubMed]
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Davies, C.; Godwin, J.; Gray, R.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; Pan, H.C.; Taylor, C.; et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011, 378, 771–784. [Google Scholar] [CrossRef]
- Barthelmes, L.; Gateley, C. Tamoxifen and pregnancy. Breast 2004, 13, 446–451. [Google Scholar] [CrossRef] [PubMed]
- Braems, G.; Denys, H.; De Wever, O.; Cocquyt, V.; Van den Broecke, R. Use of tamoxifen before and during pregnancy. Oncologist 2011, 16, 1547–1551. [Google Scholar] [CrossRef] [PubMed]
- Berger, J.C.; Clericuzio, C.L. Pierre Robin sequence associated with first trimester fetal tamoxifen exposure. Am. J. Med Genet. Part A 2008, 146, 2141–2144. [Google Scholar] [CrossRef]
- Cullins, S.L.; Pridjian, G.; Sutherland, C.M. Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation. JAMA 1994, 271, 1905–1906. [Google Scholar] [CrossRef]
- Tewari, K.; Bonebrake, R.G.; Asrat, T.; Shanberg, A.M. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 1997, 350, 183. [Google Scholar] [CrossRef]
- Zagouri, F.; Sergentanis, T.N.; Chrysikos, D.; Papadimitriou, C.A.; Dimopoulos, M.A.; Bartsch, R. Trastuzumab administration during pregnancy: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2013, 137, 349–357. [Google Scholar] [CrossRef]
- Amant, F.; Van Calsteren, K.; Halaska, M.J.; Gziri, M.M.; Hui, W.; Lagae, L.; Willemsen, M.A.; Kapusta, L.; Van Calster, B.; Wouters, H.; et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: An observational study. Lancet Oncol. 2012, 13, 256–264. [Google Scholar] [CrossRef]
- Gziri, M.M.; Amant, F.; Debiève, F.; Van Calsteren, K.; De Catte, L.; Mertens, L. Effects of chemotherapy during pregnancy on the maternal and fetal heart. Prenat. Diagn. 2012, 32, 614–619. [Google Scholar] [CrossRef] [PubMed]
- Pagani, O.; Partridge, A.; Azim, H.; Peccatori, F.; Ruggeri, M.; Sun, Z. Abstract OT3-02-01: POSITIVE: A study evaluating pregnancy and disease outcome and safety of interrupting endocrine therapy for young women with endocrine-responsive breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13). Cancer Res. 2017, 77. [Google Scholar] [CrossRef]
- Lambertini, M.; Pinto, A.C.; Ameye, L.; Jongen, L.; Del Mastro, L.; Puglisi, F.; Poggio, F.; Bonotto, M.; Floris, G.; Van Asten, K.; et al. The prognostic performance of adjuvant! Online and Nottingham prognostic index in young breast cancer patients. Br. J. Cancer 2016, 115, 1471. [Google Scholar] [CrossRef] [PubMed]
- Piccart-Gebhart, M.J.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Bell, R.; Jackisch, C.; et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1659–1672. [Google Scholar] [CrossRef] [PubMed]
- Valero, V.; Forbes, J.; Pegram, M.D.; Pienkowski, T.; Eiermann, W.; von Minckwitz, G.; Roche, H.; Martin, M.; Crown, J.; Mackey, J.R.; et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J. Clin. Oncol. 2010, 29, 149–156. [Google Scholar] [PubMed]
- Pentšuk, N.; van der Laan, J.W. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. Part B Dev. Reprod. Toxicol. 2009, 86, 328–344. [Google Scholar] [CrossRef] [PubMed]
- Konecny, G.E.; Pegram, M.D.; Venkatesan, N.; Finn, R.; Yang, G.; Rahmeh, M.; Untch, M.; Rusnak, D.W.; Spehar, G.; Mullin, R.J.; et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66, 1630–1639. [Google Scholar] [CrossRef] [PubMed]
- Giordano, S.H.; Temin, S.; Chandarlapaty, S.; Crews, J.R.; Esteva, F.J.; Kirshner, J.J.; Krop, I.E.; Levinson, J.; Lin, N.U.; Modi, S.; et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 2018, 36, 2736–2740. [Google Scholar] [CrossRef]
- Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; André, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C.; Bergh, J.; et al. 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann. Oncol. 2018, 29, 1634–1657. [Google Scholar] [CrossRef]
- De Azambuja, E.; Holmes, A.P.; Piccart-Gebhart, M.; Holmes, E.; Di Cosimo, S.; Swaby, R.F.; Untch, M.; Jackisch, C.; Lang, I.; Smith, I.; et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014, 15, 1137–1146. [Google Scholar] [CrossRef]
- Piccart-Gebhart, M.; Holmes, E.; Baselga, J.; De Azambuja, E.; Dueck, A.C.; Viale, G.; Zujewski, J.A.; Goldhirsch, A.; Armour, A.; Pritchard, K.I.; et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: Results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J. Clin. Oncol. 2016, 34, 1034. [Google Scholar] [CrossRef]
- Lambertini, M.; Martel, S.; Campbell, C.; Guillaume, S.; Hilbers, F.S.; Schuehly, U.; Korde, L.; Azim, H.A., Jr.; Di Cosimo, S.; Tenglin, R.C.; et al. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer 2019, 125, 307–316. [Google Scholar] [CrossRef] [PubMed]
- Gianni, L.; Pienkowski, T.; Im, Y.H.; Roman, L.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Staroslawska, E.; de la Haba-Rodriguez, J.; Im, S.A.; et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012, 13, 25–32. [Google Scholar] [CrossRef]
- Gianni, L.; Pienkowski, T.; Im, Y.H.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Starosławska, E.; de la Haba-Rodriguez, J.; Im, S.A.; Pedrini, J.L.; et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016, 17, 791–800. [Google Scholar] [CrossRef]
- Von Minckwitz, G.; Procter, M.; De Azambuja, E.; Zardavas, D.; Benyunes, M.; Viale, G.; Suter, T.; Arahmani, A.; Rouchet, N.; Clark, E.; et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 2017, 377, 122–131. [Google Scholar] [CrossRef] [PubMed]
- Swain, S.M.; Baselga, J.; Kim, S.B.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.M.; Schneeweiss, A.; Heeson, S.; et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 2015, 372, 724–734. [Google Scholar] [CrossRef] [PubMed]
- Yildirim, N.; Bahceci, A. Use of pertuzumab and trastuzumab during pregnancy. Anti-Cancer Drugs 2018, 29, 810–813. [Google Scholar] [CrossRef]
- A Study of Pregnancy and Pregnancy Outcomes in Women with Breast Cancer Treated with Trastuzumab, Pertuzumab in Combination with Trastuzumab, or Ado-Trastuzumab Emtansine (MotHER); Genentech, Inc.: South San Francisco, CA, USA, 2009.
- Lucy, M.; Czerniecki, B.J. Immunotherapy for breast cancer is finally at the doorstep: immunotherapy in breast cancer. Ann. Surg. Oncol. 2018, 25, 2852–2857. [Google Scholar]
- Bayraktar, S.; Batoo, S.; Okuno, S.; Glück, S. Immunotherapy in breast cancer. J. Carcinog. 2019, 18, 2. [Google Scholar] [CrossRef]
- Hepner, A.; Negrini, D.; Hase, E.A.; Exman, P.; Testa, L.; Trinconi, A.F.; Filassi, J.R.; Francisco, R.P.V.; Zugaib, M.; O’Connor, T.L.; et al. Cancer During Pregnancy: The Oncologist Overview. World J. Oncol. 2019, 10, 28. [Google Scholar] [CrossRef]
- Loibl, S.; Schmidt, A.; Gentilini, O.; Kaufman, B.; Kuhl, C.; Denkert, C.; von Minckwitz, G.; Parokonnaya, A.; Stensheim, H.; Thomssen, C.; et al. Breast cancer diagnosed during pregnancy: Adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 2015, 1, 1145–1153. [Google Scholar] [CrossRef]
- Lenhard, M.S.; Bauerfeind, I.; Untch, M. Breast cancer and pregnancy: Challenges of chemotherapy. Crit. Rev. Oncol. 2008, 67, 196–203. [Google Scholar] [CrossRef] [PubMed]
- Pavlidis, N.; Pentheroudakis, G. Metastatic involvement of placenta and foetus in pregnant women with cancer. In Cancer and Pregnancy; Springer: Berlin/Heidelberg, Germany, 2008; pp. 183–194. [Google Scholar]
- Maggen, C.; van Gerwen, M.; Van Calsteren, K.; Vandenbroucke, T.; Amant, F. Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: A review article. Int. J. Gynecol. Cancer 2019, 29, 404–416. [Google Scholar] [CrossRef] [PubMed]
- Nulman, I.; Laslo, D.; Fried, S.; Uleryk, E.; Lishner, M.; Koren, G. Neurodevelopment of children exposed in utero to treatment of maternal malignancy. Br. J. Cancer 2001, 85, 1611. [Google Scholar] [CrossRef] [PubMed]
- Avilés, A.; Neri, N. Hematological malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero. Clin. Lymphoma 2001, 2, 173–177. [Google Scholar] [CrossRef]
- Aviles, A.; Neri, N.; Nambo, M. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann. Oncol. 2005, 17, 286–288. [Google Scholar] [CrossRef]
- Van Calsteren, K.; Berteloot, P.; Hanssens, M.; Vergote, I.; Amant, F.; Ganame, J.; Claus, P.; Mertens, L.; Lagae, L.; Delforge, M.; et al. In utero exposure to chemotherapy: Effect on cardiac and neurologic outcome. J. Clin. Oncol. 2006, 24, e16–e17. [Google Scholar] [CrossRef]
- Murthy, R.K.; Theriault, R.L.; Barnett, C.M.; Hodge, S.; Ramirez, M.M.; Milbourne, A.; Rimes, S.A.; Hortobagyi, G.N.; Valero, V.; Litton, J.K. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014, 16, 500. [Google Scholar] [CrossRef]
- Cardonick, E.H.; Gringlas, M.B.; Hunter, K.; Greenspan, J. Development of children born to mothers with cancer during pregnancy: Comparing in utero chemotherapy-exposed children with nonexposed controls. Am. J. Obstet. Gynecol. 2015, 212, 658.e1–658.e8. [Google Scholar] [CrossRef]
- Amant, F.; Vandenbroucke, T.; Verheecke, M.; Fumagalli, M.; Halaska, M.J.; Boere, I.; Han, S.; Gziri, M.M.; Peccatori, F.; Rob, L.; et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N. Engl. J. Med. 2015, 373, 1824–1834. [Google Scholar] [CrossRef]
Study | Malignancy | No. of Patients | Exposure Trimesters | Follow-up Duration | Outcomes |
---|---|---|---|---|---|
Nulman et al. (2001) [99] | Various | 106 | 1T/2T/3T | 1 month– 22 years | Normal Development and school performance |
Aviles et al. (2001) [100] | Hematologic | 84 | 1T/2T/3T | 18.7 (6–29) years | Normal learning and educational performance. No congenital, neurological or psychologic abnormalities. No malignancies reported. |
Aviles et al. (2005) [101] | Hematologic | 81 | 1T/2T/3T | 17.1 (9.3–29.5) years | Normal echocardiogram. No cardiac toxicity or dysfunction. |
Van Calsteren et al. (2006) [102] | Various | 10 | 2T/3T | 2–66 months | Full neurological and cardiological examination found no abnormalities. Cortical malformation in a twin. |
Hahn et al. (2006) [55] | Breast | 40 | 2T/3T | 2–157 months | Normal development. Normal health. Normal school performance. 1 ADD. 1 Down syndrome. |
Amant et al. (2012) [73] | Various | 70 | 2T/3T | 22.3 (16.8–211.6) months | Normal growth and general health. Normal cardiac, CNS and auditory function. Normal neurocognitive development. Subtle changes in cardiac measurements were noted. Prematurity-associated lower cognitive development scores. |
Murthy et al. (2014) [103] | Breast | 50 | 2T/3T | 7 (<1–21) years | No significant toxic effects. Normal development. No significant delays in puberty. Allergies and/or eczema with higher prevalence. |
Cardonick et al. (2015) [104] | Various | 57 | 2T/3T | 18–124 months | Maternal cancer, exposed vs. unexposed to chemotherapy. No differences in: Cognitive skills. Academic performance. Behavioral competence. |
Amant et al. (2015) [105] | Various | 129 | 2T/3T | Follow-up at 18 and 36 months | In-utero exposure to various treatment types vs. matched control group (no treatment). No difference in cognitive and general development. Cardiologic evaluation at 36 months showed normal findings. Prematurity was correlated with a worse cognitive outcome independent of cancer treatment. |
O’Laughlin et al. (2019) [58] | Breast | 26 | 2T/3T | Mean 44 months | Comparison between in-utero exposure to chemotherapy + taxanes and chemotherapy alone. No difference in developmental or behavioral assessments. No medical disorders diagnosed. |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alfasi, A.; Ben-Aharon, I. Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore. Cancers 2019, 11, 1669. https://doi.org/10.3390/cancers11111669
Alfasi A, Ben-Aharon I. Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore. Cancers. 2019; 11(11):1669. https://doi.org/10.3390/cancers11111669
Chicago/Turabian StyleAlfasi, Ayelet, and Irit Ben-Aharon. 2019. "Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore" Cancers 11, no. 11: 1669. https://doi.org/10.3390/cancers11111669